Please use this identifier to cite or link to this item:
|Title:||Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.|
|Authors:||Choy, Matthew C;Seah, Dean;Faleck, David M;Shah, Shailja C;Chao, Che-Yung;An, Yoon-Kyo;Radford-Smith, Graham;Bessissow, Talat;Dubinsky, Marla C;Ford, Alexander C;Churilov, Leonid;Yeomans, Neville D;De Cruz, Peter P|
|Affiliation:||Division of Gastroenterology, McGill University, Montreal, Canada|
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Gastroenterology, St Vincent's Hospital, Melbourne, Australia
Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
Statistics and Decision Analysis Academic Platform, Florey Institute of Neuroscience & Mental Health, The University of Melbourne, Melbourne, Australia
Department of Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane Australia
The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York..
Division of Gastroenterology, McGill University, Montreal, Canada
Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Australia
Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee
Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom
|Citation:||Inflammatory bowel diseases 2019; online first: 3 January|
|Abstract:||Infliximab is an effective salvage therapy in acute severe ulcerative colitis; however, the optimal dosing strategy is unknown. We performed a systematic review and meta-analysis to examine the impact of infliximab dosage and intensification on colectomy-free survival in acute severe ulcerative colitis. Studies reporting outcomes of hospitalized steroid-refractory acute severe ulcerative colitis treated with infliximab salvage were identified. Infliximab use was categorized by dose, dose number, and schedule. The primary outcome was colectomy-free survival at 3 months. Pooled proportions and odds ratios with 95% confidence intervals were reported. Forty-one cohorts (n = 2158 cases) were included. Overall colectomy-free survival with infliximab salvage was 79.7% (95% confidence interval [CI], 75.48% to 83.6%) at 3 months and 69.8% (95% CI, 65.7% to 73.7%) at 12 months. Colectomy-free survival at 3 months was superior with 5-mg/kg multiple (≥2) doses compared with single-dose induction (odds ratio [OR], 4.24; 95% CI, 2.44 to 7.36; P < 0.001). However, dose intensification with either high-dose or accelerated strategies was not significantly different to 5-mg/kg standard induction at 3 months (OR, 0.70; 95% CI, 0.39 to 1.27; P = 0.24) despite being utilized in patients with a significantly higher mean C-reactive protein and lower albumin levels. In acute severe ulcerative colitis, multiple 5-mg/kg infliximab doses are superior to single-dose salvage. Dose-intensified induction outcomes were not significantly different compared to standard induction and were more often used in patients with increased disease severity, which may have confounded the results. This meta-analysis highlights the marked variability in the management of infliximab salvage therapy and the need for further studies to determine the optimal dose strategy.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.